XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Provided By GlobeNewswire
Last update: Dec 2, 2024
Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets
Read more at globenewswire.com24.27
+0.42 (+1.76%)
XOMA ROYALTY CORP - XOMA 8 3/8 PERP
NASDAQ:XOMAO (6/16/2025, 8:17:51 PM)
25.34
0 (0%)
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
NASDAQ:XOMAP (6/13/2025, 8:00:02 PM)
25.8229
+0.24 (+0.95%)
Find more stocks in the Stock Screener
